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Evidence of immune privilege in the eye was recorded almost 140 years ago, yet interest
in immune privilege languished for almost a century. However, the past 35 years have wit-
nessed a plethora of research and a rekindled interest in the mechanisms responsible for
immune privilege in the anterior chamber of the eye. This research has demonstrated that
multiple anatomical, structural, physiological, and immunoregulatory processes contribute
to immune privilege and remind us of the enormous complexity of this phenomenon. It is
widely accepted that immune privilege is an adaptation for reducing the risk of immune-
mediated inflammation in organs such as the eye and brain whose tissues have a limited
capacity to regenerate. Recent findings suggest that immune privilege also occurs in sites
where stem cells reside and raise the possibility that immune privilege is also designed to
prevent the unwitting elimination of stem cells by immune-mediated inflammation at these
sites. Uveal melanoma arises within the eye and as such, benefits from ocular immune priv-
ilege. A significant body of research reveals an intriguing parallel between the mechanisms
that contribute to immune privilege in the eye and those strategies used by uveal melanoma
cells to evade immune elimination once they have disseminated from the eye and establish
metastatic foci in the liver. Uveal melanoma metastases seem to have “plagiarized” the
blueprints used for ocular immune privilege to create “ad hoc immune privileged sites” in
the liver.
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INTRODUCTION
The roots of immune privilege reach back two centuries to an
observation made by the Dutch ophthalmologist van Dooremaal
(1873). In an attempt to identify the etiology of cataracts van
Dooremaal inserted a variety of foreign objects and tissues into
the eyes of rabbits and dogs. Although he failed to discover the
cause of cataracts, he observed a significant prolongation in the
survival of mouse skin grafts placed into the anterior chamber
(AC) of the dog eye (van Dooremaal, 1873). Another 75 years
would pass before Medawar “rediscovered” the prolonged sur-
vival of foreign tissue grafts placed into the AC of rabbits and
coined the term “immune privilege” to describe this phenomenon
(Medawar, 1948). Medawar concluded that the apparent absence
of lymphatic drainage from the AC resulted in a sequestration
of antigens in the eye resulting in a condition that contempo-
rary immunologists might call “immunological ignorance.” The
late 1970s ushered in a new era in immune privilege research
that was led by Streilein and colleagues who made the remark-
able observation that antigens introduced into the AC of the eye
not only gained access to the peripheral lymphoid tissues, but
in the process, induced a systemic down regulation of antigen-
specific cell-mediated immunity (Kaplan et al., 1975; Kaplan and
Streilein, 1977, 1978). This immunoregulatory phenomenon was
termed AC-associated immune deviation (ACAID; Streilein and
Niederkorn, 1981). The discovery of ACAID kindled a renewed
interest in immune privilege research that has led to numerous
insights over the past 35 years. This body of work has revealed that
immune privilege is the product of multiple anatomical, physi-
ological, and immunoregulatory processes that share a common
feature – restriction of immune inflammation in an organ whose
tissues have a severely limited capacity to regenerate.
In addition to the AC of the eye, there are other notable immune
privileged sites in the body including the testis, hair follicle, pla-
centa, and brain. The eye is part of the brain, both anatomically and
embryologically, and like the brain, has a severely limited capacity
to regenerate its tissues. Thus, immune privilege is believed to be an
adaptation to protect the eye and the brain from injury inflicted
by immune-mediated inflammation. By contrast, the testis, hair
follicle, and placenta are sites where stem cells reside. Protecting
stem cells from immune-mediated elimination has obvious sur-
vival benefits for the host and in the case of the placenta, for the
survival of the species. It is noteworthy that many of the mecha-
nisms that sustain immune privilege in the central nervous system
(i.e., eye and brain) are also employed in sites where stem cells
reside (e.g., testis, hair follicle, and placenta) and by stem cells
themselves (Arck et al., 1997; Moffett-King, 2002; Aluvihare et al.,
2004, 2005; Niederkorn, 2006; Robertson et al., 2007; Fujisaki et al.,
2011; Kinori et al., 2011; Meinhardt and Hedger, 2011; Mital et al.,
2011).
The immune system is functionally divided into two basic com-
ponents: (a) innate immunity and (b) adaptive immunity. The
innate immune response is characterized by its rapid activation
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and its conspicuous absence of antigen specificity and memory.
Components of the innate immune apparatus include natural
killer (NK) cells, macrophages, granulocytes, and the alterna-
tive pathway for complement activation. Elements of the innate
immune response serve as “first responders” to infections and pro-
vide a nimble, albeit limited level of protection, which is replaced
by the adaptive immune response. The adaptive immune system
is characterized by its exquisite antigen specificity and memory.
Although slower to develop, the adaptive immune response pro-
vides a comprehensive protection that persists longer than the
innate immune response and possesses memory that allows for
a rapid reactivation to future encounters with pathogens. Both
innate and adaptive immune responses are capable of inflicting
irreparable injury to ocular tissues and stem cells.
IMMUNE PRIVILEGE AND THE INNATE IMMUNE RESPONSE
Innate immune responses have the potential to inflict significant
irreparable damage to the eye. Granulocytes and macrophages
elaborate a variety of proteases and reactive oxygen species (ROS)
that are known to damage innocent bystander cells. However, the
aqueous humor (AH) that fills the AC is endowed with a variety of
anti-inflammatory and immunosuppressive cytokines, as well as
free radical scavengers that buffer or neutralize proinflammatory
cytokines and ROS (Taylor, 2007). Moreover, AH contains factors
that induce apoptosis of neutrophils and macrophages (D’Orazio
et al., 1999). The complement cascade can be activated through
the alternative pathway through exposure to bacterial products and
under such conditions it functions as a component of the innate
immune system. Complement activation culminates in the gener-
ation of a membrane attack complex (MAC) that punches holes in
the plasma membrane, which leads to osmotic lysis of both bacte-
rial and mammalian cells. Activation of the complement cascade
also generates soluble factors that recruit and activate neutrophils.
However, injury inflicted by complement activation is minimized
by complement regulatory proteins (CRPs) that are present in the
AH and that also decorate the membranes of cells lining the AC
(Lass et al., 1990; Bora et al., 1993; Goslings et al., 1996, 1998; Sohn
et al., 2000a).
Natural killer cells are members of the innate immune system
and are believed to protect against viral infections and neoplasms
while the adaptive immune response is still being generated. Cyto-
toxic T lymphocytes (CTLs) are important elements of the adap-
tive immune response to viral infections and neoplasms. CTLs
recognize viral antigens and tumor antigens that are displayed
on major histocompatibility complex (MHC) class I molecules.
MHC class I molecules act as the “docking station” that facilitates
the binding and cytolytic activity of CTLs. However, to evade CTL-
mediated killing many tumors and viruses down-regulate MHC
class I molecules and thereby render the cancer cells and virus-
infected cells invisible to CTLs. To compensate for this evasive
strategy, the immune system enlists the aid of NK cells, which are
programmed to kill any cell failing to express MHC class I mol-
ecules. However, the corneal endothelial cells that line the AC of
the eye and cells in the various layers of the retina express little or
no MHC class I molecules and are therefore potentially vulnerable
to NK cell-mediated cytolysis. Moreover, corneal endothelial cells
and cells of the retina are amitotic and cannot regenerate. However,
the AH contains two cytokines that inhibit NK cell-mediated
cytolytic activity. Macrophage migration inhibitory factor (MIF)
produces an immediate inhibition of NK cell-mediated cytolysis
of corneal endothelial cells (Apte and Niederkorn, 1996). Trans-
forming growth factor-β (TGF-β) also inhibits NK cell-mediated
cytolysis, but does not produce maximal inhibition for 22–24 h
(Apte and Niederkorn, 1996). Thus, the AH is endowed with mol-
ecules that produce both immediate and delayed inhibition of NK
cell activity. In addition to soluble inhibitory factors, the cells lining
the AC express non-classical MHC class Ib molecules such as HLA-
E in humans and Qa-2 in mice, which can transmit “off” signals
to NK cells (Niederkorn et al., 1999; Le Discorde et al., 2003). The
importance of intraocular inhibition of NK cell activity was con-
firmed in studies in which NK-sensitive human uveal melanoma
cells were transplanted either subcutaneously (SC) or into the AC
of nude mice. Although nude mice lack a functional T cell reper-
toire, they display potent NK cell activity. Human uveal melanoma
cells were briskly rejected by an NK cell-dependent process when
they were transplanted SC in nude mice, but grew progressively in
the eyes, even at doses that were 50-times lower than the doses that
were rejected following SC transplantation (Apte et al., 1997).
Immune privilege of innate immune responses is also present
in sites where stem cells reside such as the hair follicle, placenta,
and testis. MIF is expressed in the hair follicle (Ito et al., 2008),
Leydig cells of the testis (Meinhardt et al., 1996; Okuma et al.,
2005), and in the placenta (Vigano et al., 2007). Moreover, there
is a close association between reduced MIF in the hair follicle and
the development of alopecia areata, an autoimmune disease of the
skin (Ito et al., 2008). MIF produced by human decidual cells of
the uterus inhibits the cytolytic activity of uterine NK cells and is
believed to contribute to the immune privilege of the allogeneic
fetus (Arcuri et al., 2006; Vigano et al., 2007). As mentioned ear-
lier, non-classical class Ib MHC molecules are expressed in the eye
and are believed to be important inhibitors of NK cell-mediated
cytolysis. It is noteworthy that non-classical class Ib molecules
are also expressed in the testis (Slukvin et al., 1999; Ryan et al.,
2002) and in the placenta (Kovats et al., 1990; Ishitani and Ger-
aghty, 1992; Rouas-Freiss et al., 1997, 1999). Thus, both soluble
and cell membrane-bound molecules that inhibit innate immune
responses are expressed in both the eye and in sites where stem
cells reside (Table 1).
IMMUNE PRIVILEGE AND THE ADAPTIVE IMMUNE
RESPONSE
The adaptive immune response is characterized by exquisite anti-
gen specificity and memory. T cells and antibodies are the central
players in adaptive immune responses and each has the capacity
to produce injury to the eye. Many of the strategies employed to
buffer injurious innate immune responses in the eye and in sites
of stem cell residence are effective in blocking adaptive immune
responses that have the potential to damage stem cells and ocular
tissues that cannot regenerate.
ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE FACTORS
The AH contains at least five factors that inhibit the expression of T
cell-mediated inflammation: (a) TGF-β; (b) α-melanocyte stimu-
lating hormone (α-MSH); (c) vasoactive intestinal peptide (VIP);
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Table 1 | Factors that contribute to immune privilege in the eye and in sites of stem cell residence.
Molecule Mode of action Eye Placenta BM Testis Hair follicle
TGF-β Inhibit NK cell activity and promote generation of Tregs Y Y Y Y Y
MIF Inhibit NK cell activity Y Y ? Y Y
MHC class Ib Inhibit NK cell activity Y Y ? Y Y
IDO Deplete tryptophan and induce T cell apoptosis Y Y ? Y Y
FasL Induce apoptosis of T cells Y Y ? Y Y/N
TRAIL Inhibit T cell proliferation Y Y ? ? ?
CRPs Inactivate complement Y Y ? ? ?
PD-L1 (B7-H1) Inhibit T cell proliferation Y ? ? Y ?
Tregs Inhibit T cell immunity Y Y Y Y ?
BM, bone marrow;Y, yes; Y/N, indirect evidence; ?, not determined.
(d) calcitonin gene-related protein (CGRP); and (e) somato-
statin (Granstein et al., 1990; Cousins et al., 1991; Taylor et al.,
1994a,b; Taylor and Yee, 2003). Cells lining the AC also pro-
duce indoleamine dioxygenase (IDO), an enzyme that catabolizes
tryptophan, which is a key amino acid that is necessary for T lym-
phocyte survival (Beutelspacher et al., 2006; Ryu and Kim, 2007).
CRPs are present in the AH and are also expressed on the cell
membranes of many cells lining the interior of the eye. CRPs are
effective in maintaining immunological homeostasis within the
eye. It is believed that a low level of complement activation is
always present in the body, including the eye but under normal
homeostatic conditions, CRPs act to restrain the untoward effects
of complement activation. As evidence in support this, Sohn et al.
(2000b) reported that administration of neutralizing antibody to
CRPs in rats resulted in spontaneous ocular inflammation.
Immune privileged sites in which stem cells reside express many
of the soluble factors that are found in the AH of the eye and
are effective in suppressing adaptive immune responses (Table 1).
TGF-β is produced by Sertoli cells in the testis (Meinhardt and
Hedger, 2011), in the hair follicle (Kinori et al., 2011), and by the
placenta (Niederkorn, 2006). Moreover, murine embryonic stem
cells (ESCs) themselves upregulate TGF-β2 and create an “ad hoc”
immune privileged niche in the bone marrow (Robertson et al.,
2007). The hair follicle, placenta, and Leydig cells of the testis
elaborate α-MSH, which also suppresses T cell immunity in situ
(Niederkorn, 2006; Kinori et al., 2011; Meinhardt and Hedger,
2011). Although it is not a secreted soluble factor, IDO acts to
locally suppress T cell-mediated inflammation by depleting tryp-
tophan and starving T cells. Interestingly, IDO is present in the
anterior segment of the eye, in Sertoli cells of the testis, and in the
placenta (Mellor et al., 2001; Beutelspacher et al., 2006; Fallarino
et al., 2009).
Whether stem cells themselves contribute to the immune priv-
ilege in sites where they reside or whether they are beneficiaries of
the local immunosuppressive properties of these regions remains
unresolved. Numerous studies have reported that ESCs express
very low levels of MHC class I molecules and virtually no class
II and enjoy a significant degree of immune privilege (Drukker
et al., 2002, 2006; Li et al., 2004a; Menard et al., 2005; Bonde and
Zavazava, 2006). Moreover, adult stem cells (e.g., either mesenchy-
mal or amniotic origin) themselves display immune privilege
(Uccelli et al., 2008). By contrast, there is equally compelling
evidence that ESCs are not inherently endowed with immune
privilege and can undergo immune rejection (Nussbaum et al.,
2007; Robertson et al., 2007; Chidgey and Boyd, 2008; Swijnen-
burg et al., 2008; Wu et al., 2008). Nonetheless, it is clear that many
of the niches in which stem cells reside are classical immune priv-
ileged sites that provide a milieu that diminishes the likelihood of
inflammation and immune-mediated injury.
CELL MEMBRANE-BOUND MOLECULES
Cells that line the interior of the eye express cell membrane-bound
molecules that either induce apoptosis or inhibit proliferation of
T cells entering the eye. FasL is expressed throughout the eye
and purges activated T cells and neutrophils that enter the eye in
response to viral infections or corneal transplants (Griffith et al.,
1995; Stuart et al., 1997; Yamagami et al., 1997). PD-L1 is another
member of the B7 family of membrane proteins that induce down
regulation of T cell proliferation and cytokine production and
promote apoptosis of inflammatory cells (Dong et al., 2002; Ding
et al., 2005; Saunders et al., 2005; Okazaki and Honjo, 2007). PD-
L1 is expressed in both the mouse and human eye (Hori et al.,
2006; Shen et al., 2007; Yang et al., 2009) and is necessary for the
survival of corneal allografts (Hori et al., 2006; Shen et al., 2007).
PD-L1 is upregulated in the eyes of patients with sympathetic
ophthalmia and in ocular cells exposed to the proinflammatory
cytokines such as TNF-α and IFN-γ, which suggests that PD-L1
serves as a buffer for dampening immune-mediated inflamma-
tion of the eye (Yang et al., 2009). Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a member of the TNF fam-
ily and is expressed on cells lining the interior of the eye and is
believed to contribute to ocular immune privilege in a manner
similar to that invoked by PD-L1 (Lee et al., 2002; Wang et al.,
2003).
Cell membrane-bound molecules are also expressed in stem
cell niches. FasL is expressed on Sertoli cells of the testis (Bell-
grau et al., 1995) and on the cells of the placenta (Niederkorn,
2006). FasL message is down-regulated in the hair follicles in
patients with the autoimmune disease alopecia areata, which sug-
gests that FasL is involved in maintaining immune privilege in the
hair follicle (Kang et al., 2010). PD-L1 is found on Sertoli cells
of the testis (Dal Secco et al., 2008) and on cells of the placenta
(Petroff et al., 2003; Petroff, 2005; Holets et al., 2009). Thus, there
is an interesting parallel in the mechanisms and molecules that
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sustain immune privilege in the eye and that shield stem cells
from immune-mediated elimination.
DYNAMIC IMMUNOREGULATORY PROCESSES THAT
SUSTAIN IMMUNE PRIVILEGE
In addition to soluble and cell membrane-bound mole-
cules that dampen immune-mediated inflammation, immune
privileged sites are designed to promote the generation of
dynamic immunoregulatory processes that down-regulate adap-
tive immune responses. The seminal studies by Streilein and col-
leagues in the late 1970s introduced the paradigm of ACAID and
the concept that immune privilege was also sustained by regulatory
cells that deflected the adaptive immune response away from effec-
tor mechanisms that imposed extensive injury to collateral tissues.
A plethora of studies have revealed the complex nature of ACAID
and have demonstrated that at least four organ systems contribute
to the generation of ACAID: (a) eye; (b) thymus; (c) spleen, and (d)
sympathetic nervous system (Niederkorn, 2006, 2009; Niederkorn
and Stein-Streilein, 2010). The induction of ACAID is initiated
when antigens are introduced into the AC. Although it was origi-
nally believed that injecting antigens into the AC was tantamount
to an intravenous (IV) injection, which is a well-known method
for inducing immune tolerance (Asherson and Stone, 1965). How-
ever, the eye is not a passive participant in this process and the
immune deviation induced by AC injection of antigens is funda-
mentally different from IV-induced immune deviation (Wilbanks
and Streilein, 1990, 1991; Kosiewicz et al., 1998; Sonoda et al.,
2001). Removal of the eye within 3 days of AC injection of antigen
prevents the induction of ACAID. During this obligatory 3-day
period, it is believed that antigen is captured by F4/80+ antigen
presenting cells (APCs), which under the influence of cytokines in
the AH are imprinted to preferentially produce IL-10 and down-
regulate the production of IL-12. The ocular APC emigrate from
the eye to the thymus and spleen. Within the thymus the ocular
APCs evoke the generation of CD4−,CD8−, NK1.1+ T cells (NKT
cells), which subsequently emerge from the thymus and migrate to
the spleen via the blood vascular route (Wang et al., 1997, 2001).
Like the eye and spleen, the thymus is an active participant in
the induction of ACAID. Removing the thymus within 3 days of
AC injection of antigen prevents the induction of ACAID (Wang
et al., 1997). The sympathetic nervous system is also an active
player in the induction of AC AID, as chemical sympathectomy
prevents the induction of ACAID (Li et al., 2004b). Although it
is not clear how the sympathetic nervous system participates in
the induction of ACAID, it appears that the generation of ocular
F4/80+ APCs is not affected by the sympathetic nervous system
(Li et al., 2004b). However, chemical sympathectomy prevents the
generation of thymic NK1.1+ T cells and splenic CD8+ T regula-
tory cells (T regs; Li et al., 2004b). A population of F4/80+ ocular
APCs is also believed to migrate from the eye to the spleen where
the APCs secrete MIP-2, which attracts CD4+ NKT cells, which in
turn interact with the ocular APCs and secrete RANTES. RANTES
recruits other cells into the marginal zone of the spleen. Within
the marginal zone of the spleen, F4/80+ APCs, NKT cells, B cells,
and CD4+ T cells, under the influence of the third component
of complement, collaborate to generate antigen-specific CD8+ T
(Figure 1).
Pigmented epithelial cells of the iris and ciliary body line a por-
tion of the AC and exert important immunoregulatory effects. The
ciliary body cells secrete AH, which contains multiple immuno-
suppressive and anti-inflammatory molecules (Taylor et al., 1992,
1994a,b, 1997; Taylor and Yee, 2003; Taylor, 2007). In addition
to secreting AH, iris and ciliary body cells directly suppress T
lymphocyte proliferation and block production of IFN-γ by a
contact-dependent process that is independent of the AH-borne
soluble factors (Yoshida et al., 2000a). In vitro studies have shown
that T lymphocytes co-cultured with iris and ciliary body cells
acquire Treg activity that inhibits T lymphocyte proliferation and
antigen-specific DTH (Yoshida et al., 2000b). The in situ genera-
tion of T regs requires direct contact between T lymphocytes and
the iris and ciliary body cells. The locally generated T regs suppress
inflammation by secreting active and latent forms of TGF-β. The
only blood vessels in the anterior segment of the eye reside in the
iris and ciliary body. Thus, inflammatory cells such as T lympho-
cytes that enter the AC of the eye extravasate via the iris and ciliary
body blood vessels and as a result are in direct contact with the
pigmented cells of the iris and ciliary body and thus, are subject
to in situ induction of T reg activity. The in situ-generated T regs
greet subsequent waves of inflammatory cells that enter the AC and
impose their suppressive effects to further dampen inflammation
in the AC.
The AC possesses a second pathway for the in situ generation
of T regs. Soluble factors in the AH, namely α-MSH, can convert
T lymphocytes into CD4+CD25+ T regs that suppress DTH and
extinguish immune-mediated inflammation such as experimental
autoimmune uveitis (EAU; Nishida and Taylor, 1999; Taylor and
Namba, 2001; Namba et al., 2002).
Local induction of T reg activity also occurs in sites where
stem cells reside. The allogeneic fetus confronts the mother with
alien histocompatibility antigens of paternal origin and thus, is
at considerable risk for immune rejection. However, a wide array
of anatomical, physiological, and immunoregulatory adaptations
protect the fetus from immune rejection. The allogeneic fetus
induces a form of immune deviation with striking parallels with
ACAID. One might even argue that maternal immune privilege
is initiated even before fertilization of the ovum. Seminal fluid
contains one of the highest concentrations of TGF-β of any bodily
fluid (Robertson et al., 2002) and the TGF-β concentration in the
uterine luminal fluid increases over threefold immediately after
insemination (Tremellen et al., 1998). Semen, like AH, has the
capacity to promote the development of immune tolerance and T
regs (Lengerova and Vojtiskova, 1963; Robertson et al., 1997; James
et al., 2003). In both humans and mice, there is a steep increase in
the number of CD4+CD25+ T regs during pregnancy and deple-
tion of CD4+CD25+ T regs induces abortion in mice (Aluvihare
et al., 2004; Somerset et al., 2004). Induction of T regs also occurs
in the testis. Soluble antigens injected into the testis induce a form
of immune deviation that is reminiscent of ACAID (Li et al., 1997;
Ditzian-Kadanoff, 1999; Verajankorva et al., 2002). A recent study
demonstrated that allogeneic hematopoietic stem cell transplants
reside in the bone marrow where immune reactivity exists, yet the
stem cell transplants do not undergo immune rejection (Fujisaki
et al., 2011). Allogeneic hematopoietic stem cells reside in the bone
marrow in close proximity to CD4+CD25+ T regs. Interestingly,
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FIGURE 1 | Organ systems involved in the induction of ACAID. Removal of
the eye, spleen, or thymus within 72 h of injecting antigen into the anterior
chamber prevents the induction of ACAID. Chemical sympathectomy prior to
injecting antigen into the anterior chamber also abrogates ACAID. BCR, B cell
receptor. Reproduced from Niederkorn (2006), with permission from Nature
Publishing Group.
the hematopoietic stem cells are lost if the hosts are depleted of
CD4+CD25+ T regs (Fujisaki et al., 2011). To date no studies have
examined if the hair follicle environment promotes the induction
of immune deviation or the generation of T regs (Kinori et al.,
2011).
OCULAR IMMUNE PRIVILEGE AND OCULAR MELANOMA:
PARALLEL UNIVERSES OR IMMUNOLOGICAL PLAGIARISM?
Uveal melanoma is the most common intraocular malignancy in
adults and occurs with a frequency of seven cases per million per
year in the Western world (Singh and Topham, 2003). There is
ample evidence that uveal melanomas are recognized by elements
of both the innate and adaptive immune responses. Although
uveal melanomas reside within an immunologically privileged site
and escape immune elimination in the eye, they metastasize to
other body sites, which do not provide the same immunological
sanctuary that occurs in the eye. However, growing evidence sug-
gests that uveal melanomas have adopted many of the strategies
that contribute to immune privilege in the eye and use them to
escape immune rejection after the tumor cells have disseminated
from the eye to distant body sites (Table 2).
UVEAL MELANOMAS AND IMMUNE PRIVILEGE TO INNATE IMMUNE
RESPONSES
Studies in both humans and experimental animals indicate that
the innate immune responses, namely NK cells, have an impor-
tant influence on the growth and metastasis of uveal melanomas
(Niederkorn, 2010). In vitro studies have shown that human uveal
melanoma cells are susceptible to in vitro cytolysis by NK cells (Ma
and Niederkorn, 1995; Ma et al., 1995; He et al., 2004). However,
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Table 2 | Mechanisms and molecules that maintain immune privilege
in the eye and are “plagiarized” by uveal melanoma metastases to
escape immune surveillance.
Mechanism/
molecule
Mode of action Eye Uveal
melanoma
TGF-β Inhibit NK cells Y Y
MIF Inhibit NK cells Y Y
IDO Deplete T cells Y Y
FasL Deplete T cells Y Y
TRAIL Inhibit T cell proliferation and
induce T cell apoptosis
Y Y
CRPs Inactivate complement Y Y
PD-L1 Inhibit T cell proliferation and
induce T cell apoptosis
Y Y
Low level of MHC
class Ia
Escape detection by CTLs Y Y
MHC class Ib Inhibit NK cells Y Y
Tregs Inhibit T cells Y ?
Y, yes; ?, not determined.
the susceptibility of uveal melanoma cells to NK cell-mediated lysis
is inversely correlated with the expression of MHC class I mole-
cules (Ma and Niederkorn, 1995; Ma et al., 1995) and is consistent
with the “missing self” hypothesis, which posits that NK cells are
programmed to kill any cell, malignant or non-malignant, that fails
to express MHC class I molecules (Ljunggren and Karre, 1990).
However, within the eye uveal melanomas are shielded from NK
cell-mediated cytolysis by the buffering effects of the AH, which
contains two potent inhibitors of NK cell activity: TGF-β and MIF.
Both of these cytokines are present in the AH at concentrations that
strongly inhibit NK cell-mediated cytolysis (Apte and Niederkorn,
1996; Apte et al., 1997, 1998). Experiments in nude mice have
provided compelling evidence that AH-borne factors prevent NK
cell-mediated elimination of uveal melanomas in the eye. Nude
mice lack a functional T lymphocyte repertoire, yet have a robust
NK cell population. Uveal melanoma cells were briskly rejected
following subcutaneous transplantation in nude mice, yet grew
progressively if transplanted into the eye, even at doses 50-fold
lower than the subcutaneous doses (Apte et al., 1997). Elimina-
tion of NK cells by intraperitoneal injection of anti-asialo GM1
antiserum prevented nude mice from rejecting subcutaneously
injected uveal melanoma cells and confirmed that the rejection
of the subcutaneously injected uveal melanoma cells was indeed
mediated by NK cells and also indicated that NK cell-mediated
rejection of uveal melanoma cells can occur outside of the eye
(Apte et al., 1997).
Uveal melanomas have a propensity to metastasize to the liver
and 95% of the patients who die from uveal melanoma have
liver metastases (Einhorn et al., 1974; Donoso et al., 1985). Lym-
phocytes can infiltrate primary uveal melanomas and in some
cases, as many as 40% of the tumor-infiltrating lymphocytes (TIL)
express NK cell markers (Ksander et al., 1991; Meecham et al.,
1992; de Waard-Siebinga et al., 1996). Moreover, NK cells isolated
from uveal melanoma-containing eyes display NK cell-mediated
cytolytic activity (Ksander et al., 1991). However, as mentioned
earlier, the AH of the eye contains MIF and TGF-β, both of which
inhibit NK cell-mediated cytolytic activity in vitro and in situ.
However, once in the liver, uveal melanoma cells find themselves
in an environment that has the highest concentration of NK cells
of any organ in the body (Godfrey et al., 2000; Crispe, 2009; Gao
et al., 2009; Nemeth et al., 2009). To compensate for this harsh new
reality, uveal melanomas have adopted the strategies employed by
the eye to block NK cell-mediated cytolysis. In one study, liver
metastases of uveal melanomas produced approximately twice as
much MIF as primary uveal melanoma cells (Repp et al., 2000).
Uveal melanomas also express TGF-β2, the isoform of TGF-β
that suppresses NK cell activity (Esser et al., 2001). Verbik et al.
(1997) examined the expression of MHC class I molecules on pri-
mary uveal melanomas and liver metastases from the same patient
and discovered that liver metastases expressed a 10-fold higher
expression of MHC class I molecules compared to the primary
melanoma. The susceptibility of tumor cells to NK cell-mediated
cytolysis is also affected by the tumor cell’s expression of NK
cell activating ligands. NKG2D is an activating receptor that is
expressed on NK cells and when it interacts with its ligand, MIC-
A/B, which is expressed on NK-sensitive tumors, it transmits an
activating signal that results in NK cell-mediated cytolysis of the
tumor cells. An interesting recent study reported that MIC-A/B
was expressed on 50% of primary uveal melanomas, but was unde-
tectable on all 11 metastases specimens tested (Vetter et al., 2004).
Thus, uveal melanomas appear to undergo a selection process once
they leave the eye that favors the survival of cells that are resistant
to NK cell-mediated cytolysis.
UVEAL MELANOMAS AND IMMUNE PRIVILEGE TO ADAPTIVE IMMUNE
RESPONSES
Uveal melanomas have also high-jacked strategies used by the eye
to create “ad hoc” immune privilege against adaptive immune
responses in the liver.
IDO AND THE STARVATION OF T CELLS
T lymphocytes are incapable of generating tryptophan and per-
ish if this amino acid is absent. The enzyme IDO catalyzes the
degradation of tryptophan and thereby terminates T lymphocyte
immune responses (Munn et al., 1999; Frumento et al., 2002; Mel-
lor et al., 2002; Terness et al., 2002). IDO is expressed in many
ocular tissues and is believed to contribute to the immune privi-
lege of corneal allografts (Malina and Martin, 1993; Beutelspacher
et al., 2006; Ryu and Kim, 2007). IDO is expressed by some tumors
and is believed to be a strategy for evading immune surveillance
(Uyttenhove et al., 2003). Chen et al. (2007) reported that nei-
ther primary uveal melanomas nor liver metastases constitutively
expressed IDO. However uveal melanoma cells exposed to IFN-γ,
a cytokine produced by both T lymphocytes and NK cells, rapidly
upregulated biologically active IDO. Thus, uveal melanoma cells
are poised to generate IDO if they perceive the presence of either
adaptive or innate immune elements and thereby evade immune
elimination in the liver.
COUNTER ATTACK BY PD-L1
PD-L1 is expressed throughout the eye and sustains immune priv-
ilege by down-regulating T lymphocyte proliferation and inducing
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apoptosis of inflammatory cells expressing its receptor, PD-1. PD-
L1 also contributes to the immune privilege of corneal allografts
(Hori et al., 2006; Shen et al., 2007). In a recent study, approx-
imately half of the primary uveal melanoma cell lines tested
constitutively expressed PD-L1 and only 20% of the metastases
cell lines were positive (Yang et al., 2009). However, exposure
to the proinflammatory cytokine IFN-γ resulted in the expres-
sion of PD-L1 on primary and metastases cell lines. Thus, uveal
melanomas have the capacity to sense the presence of an inflam-
matory response in the form of IFN-γ and respond by upreg-
ulating molecules such as IDO and PD-L1 that launch a counter
attack that extinguishes immune-mediated inflammation directed
against uveal melanomas. However, this escape mechanism can
be circumvented. Uveal melanoma cells transfected with the T
cell co-stimulatory molecule, CD80, do not upregulate PD-L1
when exposed to IFN-γ and instead, activate T lymphocytes (Haile
et al., 2011). This finding suggests that unraveling the mysteries of
immune privilege may have important implications for designing
therapeutic modalities for managing malignancies such as uveal
melanoma that have adopted immune privilege as a strategy for
escaping immune surveillance.
BUFFERING EFFECTS CRPs
Complement regulatory proteins are expressed in both soluble and
cell membrane-bound forms throughout the eye and act as buffers
to limit spontaneous inflammation and complement-mediated
cytolysis of ocular cells. Uveal melanomas have high-jacked this
strategy and express all three categories of CRPs (CD46, CD55,
and CD59), which protect melanoma cells from complement-
mediated lysis in vitro and presumably in vivo (Goslings et al.,
1996). There is evidence that at least one proinflammatory
cytokine, TNF-α, up regulates CRPs on uveal melanoma cells
(Blom et al., 1997). Thus, like PD-L1 and IDO, CRPs have
the capacity to be upregulated when inflammation and possibly
adaptive immune effector elements are perceived.
CONCLUSION AND PERSPECTIVES
Our understanding of immune privilege has changed significantly
over the past 50 years. What was originally perceived as an anatom-
ical anomaly in which the putative absence of lymphatic channels
in the eye and brain acted to sequester antigens and create a state
of immunological ignorance has evolved into a more complex and
dynamic phenomenon that is the sum total of processes and mol-
ecules that prevent the induction and expression of both innate
and adaptive immunity. It is now widely accepted that immune
privilege is an adaptation to protect organs such as the eye and
brain, which have limited capacities to regenerate, from immune-
mediated injury. However, the same mechanisms and molecules
that provide immune privilege to the eye and brain are also present
in sites where stem cells reside and by stem cells themselves. Unwit-
ting injury to stem cells by immune-mediated inflammation could
have devastating consequences for the host’s survival or in the
case of the allogeneic fetus, for the survival of the species. Uveal
melanomas have “plagiarized” the blueprints used by the eye to
establish immune privilege and used them to escape immune
surveillance once the tumors leave the eye and metastasize to
the liver. Immune privilege in the eye is neither permanent nor
absolute. A variety of maneuvers can ablate immune privilege in
the eye. Perhaps the next phase of immune privilege research
is to take the lessons we have learned in abrogating immune
privilege and apply them to the treatment of uveal melanoma
metastases.
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